Researchers recently evaluated the use of a score that measures the impact growth hormone replacement therapy (GHRT) has on clinical factors associated with adult growth hormone deficiency (AGHD) and found the score was clinically different in patients who did not receive replacement therapy, according to a recent prospective, multicenter proof-of-concept study.
The Growth hormone deficiency and Efficacy of Treatment (GET) score was developed by incorporating a weighted score into six clinical factors associated with (AGHD):
• Health-related quality of life (40%)
• Bone mineral density (20%)
• Waist circumference (10%)
• Body fat mass (10%)
• Low-density lipoprotein (LDL) cholesterol (10%)
• Disease-related days off of work (10%)
“The newly developed GET score appeared to be a suitable instrument to summarize the features of AGHD and evaluate the pleiotropic response to GH substitution therapy in an integrated way,” Peter H. Kann, MD, PhD, from the Division of Endocrinology & Diabetology at Philipp’s University Marburg in Marburg, Germany, and colleagues wrote in their study. “We suggest the GET score as a tool for clinical studies rather than for routine clinical practice.”
To test the GET score, the researchers analyzed 106 patients who were treatment-naïve at baseline; of these, 53 men and 31 women received GHRT according to their physician’s usual clinical practice, while 13 men and 9 women did not receive GHRT. The baseline average for GET was 51.66 ± 20.48 points and baseline scores were similar between untreated and treated groups as well as by gender.